Results 141 to 150 of about 5,031 (196)
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Optimizing the Design of TES Tanks for Thermal Energy Storage Applications Through an Integrated Biomimetic-Genetic Algorithm Approach. [PDF]
Mehraj N +3 more
europepmc +1 more source
Bayesian Estimation Improves Prediction of Outcomes After Epilepsy Surgery
ABSTRACT We estimated the statistical power of studies predicting seizure freedom after epilepsy surgery. We extracted data from a Cochrane meta‐analysis. The median power across all studies was 14%. Studies with a median sample size or less (n ≤ 56) and a statistically significant result exaggerated the true effect size by a factor of 5.4, while the ...
Adam S. Dickey +4 more
wiley +1 more source
Spatially distributed and interconnected porous architectures for dental implants. [PDF]
Dabaja R +5 more
europepmc +1 more source
Real‐World Performance of CSF Kappa Free Light Chains in the 2024 McDonald Criteria
ABSTRACT Objective Kappa free light chains (KFLCs) in the cerebrospinal fluid (CSF) have a similar performance to CSF‐restricted oligoclonal bands (OCB) for multiple sclerosis (MS) diagnosis. To help with implementation, we set out to resolve several remaining uncertainties: (1) performance in a real‐world cohort and the 2024 McDonald criteria; (2 ...
Maya M. Leibowitz +11 more
wiley +1 more source
Opportunities in formulation development of antibody-based therapeutics. [PDF]
Hu Q, Li YF.
europepmc +1 more source
ABSTRACT Objective To determine the concentration of glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and plasma in Alexander disease (AxD) and whether GFAP levels are predictive of disease phenotypes. Methods CSF and plasma were collected (longitudinally when available) from AxD participants and non‐AxD controls.
Amy T. Waldman +9 more
wiley +1 more source
Editorial: Emerging materials and structures for future renewable energy conversion and large-scale storage technology. [PDF]
Que W, Yin X, Yang Y, Shen F.
europepmc +1 more source
Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy
ABSTRACT Objective Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.
Roxane Dilcher +10 more
wiley +1 more source
Unbiased mechanical cloaks. [PDF]
Senhora FV, Sanders ED, Paulino GH.
europepmc +1 more source

